Europe Veterinary Pharmaceuticals Market To Reach $ 17.1 Billion By 2033

Europe Veterinary Pharmaceuticals Market Growth & Trends

The Europe veterinary pharmaceuticals market size is expected to reach USD 17.1 billion by 2033, registering a CAGR of 10.3% from 2026 to 2033, according to a new report by Grand View Research, Inc. The key factors anticipated to fuel the market growth include increasing demand for companion animal products, pet expenditure, the prevalence of diseases in companion as well as livestock animals, and initiatives by the market players. For instance, in September 2020, Boehringer Ingelheim collaborated with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME to develop sustainable veterinary antiparasitics that are safe and effective.

The COVID-19 pandemic significantly impacted the market leading to bottlenecks in the supply chain and reduced sales for several companies. Other impacts on the market include reduced R&D activities, low demand, and operational hurdles due to changing policies and restrictions. However, soon governments, regulatory bodies, and companies began implementing measures to help the economy and businesses recover. These measures included the easing of restrictions, monetary stimulus and policy changes, conditional exemptions, and other initiatives. As on-site GMP inspection visits were disrupted due to COVID-19, the EMA extended the validity of GMP certificates till the end of 2021 without any further action from the holder. These included manufacturing or import sites of active substances as well as finished products located in the EEA region.

In addition, to ensure an uninterrupted supply of veterinary medicines in the EU Member States, product information and labeling regulations were relaxed. For instance, during the pandemic and within the boundaries of Article 61(1) of Directive 2001/82/EC, member states may allow exemptions for labeling and packaging requirements for veterinary products such as not translating labels into the official language and so on.

The rising pet population and increasing expenditure on pets have led to a surge in demand for companion animal products, such as pet foods, pharmaceuticals, and veterinary services. This trend is estimated to continue over the forecast period. For instance, a 2020 report by FEDIAF estimated the annual sales of pet food products at about EUR 21.8 billion. Across the European region, the rise in single-person or small households, along with the rising geriatric population, is also expected to contribute to the growing pet population. In addition, the COVID-19 pandemic has catalyzed market growth with a surge in pet adoption. In January 2021, Deutsche Welle— a German media company reported an exponential rise in pet ownership in the country.

Competition in the European market for veterinary medicines is expected to remain high during the forecast period. The market is highly fragmented owing to the presence of several small and large players. This results in high competition among small players to sustain their market position. Moreover, companies are increasingly adopting various strategies, such as mergers & acquisitions, regional expansion, and product launches, to grow in the market. For instance, in August 2021, Elanco accelerated its expansion strategy in the pet health industry through the acquisition of Kindred Biosciences. This complemented the company’s Innovation, Portfolio, & Productivity (IPP) strategy and added three potential dermatology blockbusters estimated to be launched by 2025, to its lineup.

 Request a free sample copy or view report summary: Europe Veterinary Pharmaceuticals Market Report

Europe Veterinary Pharmaceuticals Market Report Highlights

• The production animal segment accounted for the largest share of 65.4% in 2025.The segment includes cattle, pigs, sheep, goats, poultry, and other livestock species that require pharmaceutical products to prevent and treat infectious diseases, parasitic infestations, inflammatory conditions, and other animal health disorders.

• The parasiticides segment dominated the Europe veterinary pharmaceuticals market, accounting for 35.1% of the market in 2025. The segment is driven by the widespread need to prevent and treat endoparasitic and ectoparasitic infestations across companion and livestock animals.

• The branded segment accounted for the largest market share of 58.6% in 2025. This is attributed to the presence of established veterinary pharmaceutical companies, strong brand recognition, and veterinarians' familiarity with existing products.

• The prescription segment accounted for the largest market share of 62.0% in 2025. This is attributed to the need for veterinary diagnosis and professional supervision when treating complex animal diseases.

• The oral segment accounted for the largest market share of 43.3% in 2025, driven due to the ease of administration, convenience, and wide availability of veterinary medicines in the form of tablets, capsules, liquids, and powders.

• The institutional sales segment led the Europe veterinary pharmaceuticals market, accounting for the largest revenue share of 42.6% in 2025. The segment is fueled by regular pharmaceutical purchases by veterinary hospitals, clinics, commercial livestock producers, and integrated farms.

Europe Veterinary Pharmaceuticals Market Segmentation

Grand View Research has segmented the Europe veterinary pharmaceuticals market on the basis of animal type, product, drug type, type, route of administration, sales channel, and country:

Europe Veterinary Pharmaceuticals Animal Outlook (Revenue, USD Million, 2021 - 2033)

• Production Animals

  • Poultry

  • Swine

  • Bovine

  • Ovine & Caprine

  • Others

• Companion Animals

  • Canine

  • Feline

  • Equine

  • Others

Europe Veterinary Pharmaceuticals Product Outlook (Revenue, USD Million, 2021 - 2033)

• Parasiticides

• Anti-infectives

• Anti-inflammatory

• Analgesics

• Other Products

Europe Veterinary Pharmaceuticals Drug Type Outlook (Revenue, USD Million, 2021 - 2033)

• Branded

• Generics

Europe Veterinary Pharmaceuticals Type Outlook (Revenue, USD Million, 2021 - 2033)

• Prescription

• OTC

Europe Veterinary Pharmaceuticals Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)

• Oral

• Injectable

• Topical

• Other Routes

Europe Veterinary Pharmaceuticals Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)

• Institutional Sales

• Veterinary Pharmacies & Retail

• E-Commerce

• Other Channels

Europe Veterinary Pharmaceuticals Regional Outlook (Revenue, USD Million, 2021 - 2033)

• UK

• Germany

• France

• Italy

• Spain

• Denmark

• Sweden

• Norway

List of Key Players in the Europe Veterinary Pharmaceuticals Market

• Merck & Co., Inc.,

• Ceva

• Vetoquinol

• Zoetis Services LLC

• Boehringer Ingelheim International GmbH

• Elanco

• Virbac

• Calier

• Bimeda Corporate

• Prodivet Pharmaceuticals SA/NV